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CASE4 DIABETES PHYSICIAN RECOGNITION IN A LARGE HEALTH PLAN
Kramer M 1 , Perez HE 2 , Stacy T 2 1 Aetna, Brunswick, MD, USA, 2 Total Therapeutic Management Inc, Kennesaw, GA, USA ORGANIZATION: Aetna Inc. is one of the nation's leading diversifi ed health care benefi ts companies, serving approximately 37.2 million people. PROBLEM OR ISSUE ADDRESSED: To increase the number of physicians that are NCQA Diabetes Physician Recognition Program (DPRP) recognized in two pilot regions. GOALS:
(1) To increase the number of high-volume Aetna contracted practitioners (PCPs) located in targeted geographic areas (South Florida and Southeast PA) with Diabetes Physician Recognition Program (DPRP) recognition (2) To provide physicians with tools to support the delivery and recognition of consistent high quality care. OUTCOMES ITEMS USED IN THE DECISION: Clinical effi cacy/effectiveness IMPLEMENTATION STRATEGY: The Aetna National Quality Management Diabetes Work Group met and agreed on the implementation of a three phase program to increase the number of NCQA DPRP recognized practitioners. Aetna conducted an analysis of two service areas (South FL and Southeastern PA) to rank the high volume Aetna contracted practitioners with the most Aetna members over the age of 18 with a diagnosis of diabetes. The member must have been under the care of the practitioner in calendar year 2007. For the practitioner to qualify he must have at least 25 Aetna members meeting this criteria. Forty practitioners were recruited into the program (20 from each service area). Aetna utilized Total Therapeutic Management (TTM), a research organization, to implement the three phase program. In phase 1, TTM recruited the qualifying practitioners and conducted an in-offi ce chart review to abstract data consistent with the Comprehensive Diabetes Care Healthcare Effectiveness Data and Information Set (HEDIS ) measures. TTM utilized its Diabetes Performance and Enhancement Program (DPReP) electronic application to provide the practitioners with a report to see if they met the point criteria for recognition. In phase 2, TTM conducted face-to-face outreach to discuss recognition standing, patient consults (ClinAdvisor), and pharmacy compliance reports. The ClinAdvisor patient consults detailed clinical outcomes such as, A1C, BP, LDL goal, etc. Also during the visit Aetna-developed tools were provided such as chart stickers, eye exam report forms, and 3-year diabetes checklist to promote quality improvement in tracking and managing members with diabetes. TTM communicated with the practitioner during the sixmonth waiting period in areas that needed improvement. In phase 3, TTM conducted chart reviews based on the criteria set forth by NCQA. TTM input the abstracted data into its electronic application to evaluate recognition status. RESULTS: In order to achieve diabetes recognition, practitioners must have a cumulative score of 75 points or more from ten measures related to diabetes care. Of the 40 practitioners that participated in the program four had the potential points necessary to meet the recognition standing score of 75 points in the initial evaluation. After the second review conducted approximately six months after the fi rst review, 18 practitioners agreed to participate in phase 3. Of the 18 practitioners participating, 17 practitioners met the criteria for DPRP recognition. LESSONS LEARNED: Practitioners are aware of the benefi ts of Pay for Performance initiatives. They are also aware of the various recognition programs available through NCQA. Practitioners have expressed concern about the time or offi ce staff necessary to conduct their own chart reviews and submit the application to become a recognized provider. If there is a process in place to conduct chart reviews and provide chart review-based recommendations and other practitioner tools, there is a strong possibility that more practitioners can meet the requirements set forth by NCQA to become a DPRP recognized provider for diabetes and other conditions.
CASE5 HARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENT: A CASE STUDY OF ERLOTINIB AT A MAJOR CANCER CENTER
Lal LS 1 , Ugwu C 2 , DaCosta Byfi eld S 1 , Miller LA 1 , Arbuckle R 1 1 University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, 2 University of Houston, Houston, TX, USA ORGANIZATION: University of Texas-MD Anderson Cancer Center (M. D. Anderson). PROBLEM OR ISSUE ADDRESSED: Budgets for cancer treatments are rising steadily with the advent of newer targeted therapies, in an era of health care cost containment. The issues of budgetary constraints and formulary management create pressure on maintaining an economically viable formulary. We conducted a preapproval and post-approval analysis of erlotinib, an oral anti-neoplastic agent, in stage IIIB/IV non-small cell lung cancer (NSCLC) in the outpatient and inpatient setting at a tertiary cancer center as part of our Formulary Management System (FMS). GOALS:
The goal of this study is to evaluate and analyze the budget impact of erlotinib in stage IIIB/IV NSCLC at a tertiary cancer center. The objective of the Drug Use Policy and Pharmacoeconomic Department is to utilize current clinical indications, resource utilization, and cost information to perform a budget impact analysis, as part of the economic analysis of all new drugs considered for inclusion into the institutional Formulary. An economic assessment (pre-analysis) was conducted at the time of formulary evaluation and addition in May 2005, and a reassessment and budget impact re-evaluation (post-analysis) was executed 12 months after formulary approval, from June 2006 to May 2007. OUTCOMES ITEMS USED IN THE DECISION: The following data were collected: the number of patients; the dose amount; the number of doses; the number of cycles; the purchase cost, the charge amount; and the reimbursement amount. The budget impact analysis was executed using direct pharmaceutical costs adjusted to January 2008 US dollars with the aid of the Producer Price Index (PPI) from the U.S. Bureau of Labor Statistics. IMPLEMENTATION STRATEGY:
The pre-approval model was based on the FDA approval of erlotinib as a second line therapy in stage IIIB/IV NSCLC. Parameters, such as median duration of treatment and indications, were gathered from published clinical trials and the expected number of patients were estimated from expert opinion of clinicians. The pre-approval analysis model estimated that it would cost the institution $1,484,220 to treat 347 stage IIIB/IV NSCLC patients for 67 days with erlotinib. This data along with a monograph was presented to the Pharmacy and Therapeutics (P&T) committee and the drug was approved to be added to the institutional Formulary. RESULTS: A reassessment and budget impact (post-approval) analysis was executed 12 months after erlotinib was inducted into the formulary. The analysis reviewed the non-investigational use of erlotinib from June 2006 to May 2007. We had 306 patients that received erlotinib during that time. The number of patients using erlotinib in the outpatient setting was 267 (87%), and on the inpatient side 39 (13%) patients utilized the drug. 155 patients (51%) received erlotinib as second or third line therapy for treatment of stage IIIB/IV NSCLC, which is lower than what the pre-approval model predicted. Sixty patients (20%) were on erlotinib as fi rst-line therapy for locally advanced, unresectable, or metastatic pancreatic cancer, a second indication for the drug, attained after addition to the institutional formulary. Finally, ninety-one patients (30%) were on erlotinib for other non-FDA approved caner indications. The overall annual budget for total erlotinib usage was similar to the initial model, $1,473,085. The budget specifi cally for NSCLC was lower at $858,904, only 58% of the predicted amount. One possible reason for the lower than predicted budget impact is that erlotinib is an oral agent, which gives patients the option of obtaining the drug from an outside pharmacy closer to their home, rather than utilizing the institutional pharmacy. We also evaluated the reimbursement data for these patients, from June 2006 to May 2007, adjusting all values to January 2008 dollars. The reimbursement to charge ratio for NSCLC was 65%; 62% for pancreatic cancer; and 65% for the other non-FDA approved indications. Overall, the reimbursement to charge ratio for all 306 patients was 64%, which is favorable to our budget expectations at the institution. LESSONS LEARNED: The purpose of this assessment and budget impact analysis pre-and post-approval of the drug onto the formulary is to evaluate the budget impact of having erlotinib on the formulary, assessing our actual utilization patterns. We were able to meet the reimbursement goals for the institution for all indications of erlotinib. Performing an annual budget impact evaluation before addition of a drug to an institution's formulary, and comparing it with the annual budget impact after a suffi cient time has elapsed for penetration of product within the institution, is an essential process in determining the best use of expensive resources. Continued improvements to this process are ongoing, by incorporating off-label estimates into the original model.
CASE6 PILOT PROJECT: INTEGRATING ADMINISTRATIVE AND FINANCIAL DATABASES TO ESTIMATE PRICE OF HOSPITALIZATIONS
Wong H g 1 , Levit K 2 1 Agency for Healthcare Research and Quality, Rockville, MD, USA, 2 Thomson Reuters/ Agency for Healthcare Research and Quality, Washington, DC, USA ORGANIZATION: Agency for Healthcare Research and Quality (funding organization) Thomson Reuters. PROBLEM OR ISSUE ADDRESSED: Hospital administrative data have been used in "cost-effectiveness", "cost-benefi t", and "burden-of-illness" studies because they contain large numbers of cases for specifi c conditions and procedures and because charge information is available. While these data generally contain information on how much the facility charged for the hospital stay, they lack information on the cost to provide care and the amount reimbursed for care. In the past, AHRQ developed a set of hospital-level cost-to-charge ratios to estimate the cost of providing care. Currently, AHRQ is piloting a project to create price-to-charge ratios that will be used in conjunction with charge information collected on hospital discharge records to estimate the "price" of inpatient hospital care. In developing priceto-charge ratios, the term "price" refl ects the amount that hospitals are paid by insurers and consumers based on payer revenue information for each hospital. This is the amount of revenue that hospitals actually receive, net of any discounts negotiated with insurers. These ratios will be linked to the Healthcare Cost and Utilization Project (HCUP) State Inpatient Databases (SID). The HCUP SID fi les contain the universe of inpatient discharge abstracts (including information on charges) in participating States, translated into a uniform format to facilitate multi-State comparisons and analyses. Currently, 40 states participate in HCUP, encompassing about 90 percent of all U.S. community hospital discharges. The impetus for this pilot is the President's and Secretary Leavitt's initiatives to make health care information more transparent to consumers. While the addition of price information will help consumers make more informed choices about hospitalizations for themselves and their families, this information will also be valuable for researchers by providing alternatives to measuring resource use that are better suited for their studies. GOALS: The short-term goals of this project include: • Explore the feasibility of creating prices for common hospital diagnoses. • Release prices at a state-wide level for four broad payer groups (Medicare, Medicaid, Private, and self-pay) and groupings of conditions. • Increase understanding of pricing differences among payers. • Release the data publicly after some internal validation. The long term goals of this project include: • Develop price-to-charge ratios for all hospitals by payer states using modeling techniques. • Link price-to-charge ratios to the HCUP databases, which currently contain charge information and estimate costs. • Validate estimated prices with data sources such as CMS, Market Scan, • Provide states with information on hospital average prices that can be used to populate a Website where consumers can explore pricing for common diagnoses. • Release prices publicly on additional AHRQ databases, including national databases such as the Nationwide Inpatient Sample (NIS) and Kids' Inpatient Database (KID). OUTCOMES ITEMS USED IN THE DECISION: HCUP data have been used in "cost-effectiveness", "cost-benefi t", and "burden-of-illness" studies because they contain large numbers of cases for specifi c conditions and procedures and because charge and estimated cost information is available. The addition of estimates prices will provide researchers an additional tool to more effectively conduct their studies. IMPLEMENTATION STRATEGY: AHRQ solicited participation of HCUP Partner organizations that have access to hospital revenue information by payer, and are willing to release state-level charge and price information broken out by the four broad payer groups and broad diagnostic categories. Initially, AHRQ is utilizing information from 5 HCUP SID Partner States in conjunction with hospital-specifi c revenue information to develop prices for hospitalizations. RESULTS: This project is on-going and making substantial progress. Five states with the required fi nancial information have been identifi ed. The analytic methods to validate the data have been determined. The plan to create the price-to-charge ratios for these states is in place. An illustrative example of a specifi c condition or procedure will be provided during the presentation to demonstrate the differences in resource use as measured by "charges," "costs," and "prices." An explanation of what these concepts are capturing will also be presented. LESSONS LEARNED: To date, the project the lessons learned include: 1. The number of States that collect fi nancial information by major payers for each hospital are limited. 5 States have been identifi ed that have the detailed information required. As the study moves forward, our objective is to identify 8-10 states with this level of information. 2. While States may collect gross and net revenue information by payer, not all separate these revenues completely for inpatient and outpatient services. Methods will be developed to address this issue. 3. Defi nitions of revenues and the level of detailed data collection vary considerably among States. These differences will be reconciled.
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